Randomized phase II study comparing S-1 plus Leucovorin (SL) versus S-1 alone in patients with gemcitabine-refractory advanced pancreatic cancer (APC)

被引：0
|
作者：
Okusaka, T. [1 ]
Ueno, M. [2 ]
Omuro, Y. [3 ]
Isayama, H. [4 ]
Fukutomi, A. [5 ]
Ikeda, M. [6 ]
Mizuno, N. [7 ]
Fukuzawa, K. [8 ]
Hyodo, I. [9 ]
Boku, N. [10 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Kanagawa Canc Ctr, Div Hepatobiliary & Pancreat Med Oncol, Kanagawa, Japan
[3] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Chemotherapy, Tokyo, Japan
[4] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan
[5] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[6] Natl Canc Ctr Hosp East, Div Hepatobiliary & Pancreat Oncol, Chiba, Japan
[7] Aichi Canc Ctr Hosp, Dept Gastroenterol, Nagakute, Aichi, Japan
[8] Oita Red Cross Hosp, Dept Surg, Oita, Japan
[9] Univ Tsukuba, Div Gastroenterol, Tsukuba, Ibaraki, Japan
[10] St Marianna Univ, Sch Med, Dept Clin Oncol, Kawasaki, Kanagawa, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2578
引用
收藏
页码：S611 / S611
页数：1
相关论文
共 50 条
  • [1] A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
    Ueno, M.
    Okusaka, T.
    Omuro, Y.
    Isayama, H.
    Fukutomi, A.
    Ikeda, M.
    Mizuno, N.
    Fukuzawa, K.
    Furukawa, M.
    Iguchi, H.
    Sugimori, K.
    Furuse, J.
    Shimada, K.
    Ioka, T.
    Nakamori, S.
    Baba, H.
    Komatsu, Y.
    Takeuchi, M.
    Hyodo, I.
    Boku, N.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 502 - 508
  • [2] Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer.
    Ueno, Makoto
    Ohkawa, Shinichi
    Kobayashi, Noritoshi
    Sugimori, Kazuya
    Kawaguchi, Yoshiaki
    Kobayashi, Satoshi
    Taguri, Masataka
    Yamanaka, Takeharu
    Mine, Tetsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [3] Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer
    Mizuno, Nobumasa
    Yamao, Kenji
    Komatsu, Yoshito
    Munakata, Masaki
    Ishiguro, Atsushi
    Yamaguchi, Taketo
    Ohkawa, Shinichi
    Kida, Mitsuhiro
    Ioka, Tatsuya
    Takeda, Koji
    Kudo, Toshihiro
    Kitano, Masayuki
    Iguchi, Haruo
    Tsuji, Akihito
    Ito, Tetsuhide
    Tanaka, Masao
    Furuse, Junji
    Hamada, Chikuma
    Sakata, Yuh
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [4] Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
    S Ohkawa
    T Okusaka
    H Isayama
    A Fukutomi
    K Yamaguchi
    M Ikeda
    A Funakoshi
    M Nagase
    Y Hamamoto
    S Nakamori
    Y Tsuchiya
    H Baba
    H Ishii
    Y Omuro
    M Sho
    S Matsumoto
    N Yamada
    H Yanagimoto
    M Unno
    Y Ichikawa
    S Takahashi
    G Watanabe
    G Wakabayashi
    N Egawa
    M Tsuda
    R Hosotani
    C Hamada
    I Hyodo
    British Journal of Cancer, 2015, 112 : 1428 - 1434
  • [5] Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
    Ohkawa, S.
    Okusaka, T.
    Isayama, H.
    Fukutomi, A.
    Yamaguchi, K.
    Ikeda, M.
    Funakoshi, A.
    Nagase, M.
    Hamamoto, Y.
    Nakamori, S.
    Tsuchiya, Y.
    Baba, H.
    Ishii, H.
    Omuro, Y.
    Sho, M.
    Matsumoto, S.
    Yamada, N.
    Yanagimoto, H.
    Unno, M.
    Ichikawa, Y.
    Takahashi, S.
    Watanabe, G.
    Wakabayashi, G.
    Egawa, N.
    Tsuda, M.
    Hosotani, R.
    Hamada, C.
    Hyodo, I.
    BRITISH JOURNAL OF CANCER, 2015, 112 (09) : 1428 - 1434
  • [6] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Morizane, Chigusa
    Okusaka, Takuji
    Furuse, Junji
    Ishii, Hiroshi
    Ueno, Hideki
    Ikeda, Masafumi
    Nakachi, Kohei
    Najima, Mina
    Ogura, Takashi
    Suzuki, Eiichiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 313 - 319
  • [7] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Chigusa Morizane
    Takuji Okusaka
    Junji Furuse
    Hiroshi Ishii
    Hideki Ueno
    Masafumi Ikeda
    Kohei Nakachi
    Mina Najima
    Takashi Ogura
    Eiichiro Suzuki
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 313 - 319
  • [8] RANDOMIZED PHASE II TRIAL OF S-1 VERSUS S-1 PLUS OXALIPLATIN (SOX) IN PATIENTS WITH GEMCITABINE REFRACTORY PANCREATIC CANCER
    Okusaka, T.
    Ohkawa, S.
    Isayama, H.
    Fukutomi, A.
    Yamaguchi, K.
    Ikeda, M.
    Funakoshi, A.
    Nagase, M.
    Nakamori, S.
    Hamamoto, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 241 - 242
  • [9] TAS-118 (S-1 plus leucovorin) versus S-1 in gemcitabine-refractory advanced pancreatic cancer: A randomized, open-label, phase III trial (GRAPE trial).
    Ueno, Makoto
    Ioka, Tatsuya
    Ueno, Hideki
    Park, Joon Oh
    Chang, Heung-Moon
    Sasahira, Naoki
    Kanai, Masashi
    Chung, Ik-Joo
    Ikeda, Masafumi
    Nakamori, Shoji
    Mizuno, Nobumasa
    Omuro, Yasushi
    Yamaguchi, Taketo
    Hara, Hiroki
    Sugimori, Kazuya
    Furuse, Junji
    Takeuchi, Masahiro
    Okusaka, Takuji
    Boku, Narikazu
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
    T Ioka
    Y Komatsu
    N Mizuno
    A Tsuji
    S Ohkawa
    M Tanaka
    H Iguchi
    A Ishiguro
    M Kitano
    T Satoh
    T Yamaguchi
    K Takeda
    M Kida
    K Eguchi
    T Ito
    M Munakata
    T Itoi
    J Furuse
    C Hamada
    Y Sakata
    British Journal of Cancer, 2017, 116 : 464 - 471
12345